WHAT IS MDAI?
MDAI , 5,6-Methylenedioxy-2-aminoindane (commonly known as MDAI) is an entactogen substance of the aminoindane chemical class that produces entactogenic effects when administered. Notably, this compound primarily produces the non-stimulating effects of prototypical entactogens like MDMA such as sedation, muscle relaxation, and tactile enhancement.
MDAI was developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a putatively non-neurotoxic and highly selective serotonin releasing agent (SSRA) with neglible effects on dopamine and norepinephrine. This reportedly limits its potential at producing overtly invigorating, prosocial or euphoric effects.
MDAI has been marketed alongside research chemical entactogens like 5-MAPB, 5-APB, and 6-APB as a legal, grey-market alternative to MDMA.
Always consult your healthcare provider to ensure the information displayed here applies to your personal circumstances.